UBS analyst Marcus Curley reiterated a Buy rating and $285.00 price target on ResMed (NYSE: RMD).The analyst commented, "Apnimed, a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE